Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
about
Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemiaClustered precursors in bone marrow sections predict early relapse in patients with acute myeloid leukemia within hematologic remissionHypomethylating agents for adult patients with acute myeloid leukaemiaThe role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionThe role of maintenance therapy in acute promyelocytic leukemia in first complete remissionHypomethylating agents for adult patients with acute myeloid leukaemiaEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyClinical study of Mito-FLAG regimen in treatment of relapsed acute myeloid leukemiaHistone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsA phase 2 study of vorinostat in acute myeloid leukemiaConstitutively active SHP2 cooperates with HoxA10 overexpression to induce acute myeloid leukemiaAcute Myeloid Leukemia: A Concise ReviewMonitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesA meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndromeMutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patientsPrognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.Ponatinib in refractory Philadelphia chromosome-positive leukemias.Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Novel therapeutic options in Acute Myeloid LeukemiaThe Danish National Acute Leukemia RegistryOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaAdult acute erythroleukemia: an analysis of 91 patients treated at a single institutionPhase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemiaDeregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistanceAcute myeloid leukaemia: challenges and real world data from IndiaHistone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid LeukemiaEfficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaEvaluation of BM cytomorphology after allo-SCT in patients with AML.Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaData quality in the Danish National Acute Leukemia Registry: a hematological data resourceAddition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.Platelet factor-4 is an indicator of blood count recovery in acute myeloid leukemia patients in complete remission.The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative GrouAzacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group
P2860
Q21132375-E0C517C6-9271-4341-8A9C-738F13F66B2CQ21245489-7F978F23-B5DE-44B1-AB0E-8B9789EB2FC0Q24186284-07D4CB4E-AFAC-4CA7-BECC-1A58D4347C63Q24200224-D17E4658-1135-4A21-B47E-4C60E6B73191Q24203970-37BE7FB7-A8DE-45F1-8C72-FA46196E1E0BQ24234645-AD82DC24-16FE-4B2D-BBBB-63FCE7CC1882Q24563021-BA96FD01-45B1-4184-AEEB-4FB22544E4B7Q24621923-C7FAA606-6C55-4EDB-A2E7-3163DE9E59E5Q24633763-6BE7EC48-2734-4E04-8D05-E59984ACD5FCQ24643266-69DB46BC-0B5F-41C6-A337-952EF4CF28FEQ24646924-C651ACFA-9313-411E-B2E0-7917903CDB2CQ26766719-54620010-DE0E-48C4-B3A4-4E3877DC2F79Q26770394-B7A5F2D7-A9E8-4388-BE59-ECE58332B005Q27024786-033A4311-2517-490F-9E78-A6784C85B0CAQ27851423-5105894A-C1BE-4575-81B4-F125D254B31DQ27851579-8B2D0231-9DB0-4937-899A-9844AB165BD6Q27851636-66ED3479-ED22-4055-8664-9BF5822B3D76Q27851642-5573A3E2-4A36-4CD9-A738-34D52D1F95A8Q27851686-4B2DCC05-87FA-47CE-AE70-2DA4B05B10CCQ27851909-4BCA406B-BC8A-4A0F-B640-99C78FBD1B57Q27851967-E849DE91-8E86-491F-9919-9FD92ABA1F71Q27852623-974B28FA-E41E-490C-B733-4D5019EED869Q28069889-CD354537-C84D-4962-B7C7-BA5CC33358D8Q28075468-75B01B37-C96B-4ECB-A60E-050581450921Q28084813-24C4A1E3-9384-4291-8C26-91CFB24DFDFAQ28258018-46DE5DA3-DB3C-495A-8415-1E36D1721D01Q28271726-953F2FC9-5E69-43FB-86BC-728D014221A7Q28538139-B374522D-7B26-4430-87B7-FC1C6CE3BF1AQ28602934-5F948A61-08FE-4298-8622-203F08CE8071Q29394054-D8C00B94-B6FC-4E53-946B-031729AB2415Q29617590-A593B1B6-8253-4058-9E24-8743634FEFCEQ30318110-AE0B58D9-ED14-419A-92E8-DA6EE483A71EQ30399209-4F6E62AD-FA51-49FE-86E5-AAB30F2B4EB4Q30449092-FAA493F8-5332-483D-88A9-FBE58D28358EQ30497200-9ADBFFB4-521A-4637-8AFE-F2AB1FB47BDFQ30667157-3AB3E891-432E-41EC-B3ED-170FC6C65328Q30835785-0E4D299B-ECA7-48F9-BAE1-AD3FF46E4704Q30838366-6FED7C10-3A70-4052-95BC-54B4CDD75E1FQ31143348-83761C02-FB2A-4246-9578-C2D9AB8EEA09Q31163049-FC86354C-6BAD-4F65-8A60-E964A7D47538
P2860
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Revised recommendations of the ...... als in Acute Myeloid Leukemia.
@en
type
label
Revised recommendations of the ...... als in Acute Myeloid Leukemia.
@en
prefLabel
Revised recommendations of the ...... als in Acute Myeloid Leukemia.
@en
P2093
P50
P356
P1476
Revised recommendations of the ...... als in Acute Myeloid Leukemia.
@en
P2093
Andrea Biondi
Bruce D Cheson
Charles A Schiffer
Cheryl L Willman
David R Head
Elihu H Estey
Hartmut Doehner
International Working Group fo ...... ials in Acute Myeloid Leukemia
John M Bennett
Kenneth J Kopecky
P304
P356
10.1200/JCO.2003.04.036
P407
P577
2003-12-01T00:00:00Z